, Tracking Stock Market Picks
Enter Symbol:
Advaxis, Inc. (ADXS) [hlAlert]

up 163.09 %

Advaxis, Inc. (ADXS) rated Buy with price target $18 by Aegis Capital

Posted on: Tuesday,  Feb 18, 2014  8:25 AM ET by Aegis Capital

Aegis Capital rated Buy Advaxis, Inc. (NASDAQ: ADXS) on 02/18/2014, when the stock price was $5.69. Since
then, Advaxis, Inc. has gained 163.09% as of 01/21/2016's recent price of $14.97.
If you would have followed this Aegis Capital's recommendation on ADXS, you would have gained 163.09% of your investment in 702 days.

Advaxis, Inc. is a development-stage biotechnology company with the focus on developing cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania (Penn), which secretes a protein sequence containing a tumor-specific antigen. This technology involves the creation of genetically engineered Listeria that stimulates the innate immune system and induces an antigen-specific immune response involving both arms of the adaptive immune system. The Company?s products in development are ADXS11-001, ADXS31-142 and ADXS31-164. The Company uses genetically engineered and attenuated Listeria monocytogenes as a therapeutic agent. The Company?s agent ADX11-001, uses a human papilloma virus (HPV) derived antigen that is present in cervical cancers.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/18/2014 8:25 AM Buy
5.69 18.00
as of 10/17/2014
1 Week up  9.59 %
1 Month down  -7.76 %
3 Months up  7.22 %
1 YTD down  -47.80 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy